Rybelsus is not subsidised on the PBS for weight management, so patients pay the full private price, which varies by pharmacy and dose
In a randomized double-blind placebo-controlled study, participants consuming Reducose with sucrose (sugar) experienced significantly lower postprandial glucose and insulin responses compared to placebo
Target Audience Target Audience Pharmaceutical Companies Developing Obesity and Metabolic Drugs Oral GLP-1, Dual Incretin and Triple Agonist Drug Developers Biotechnology Companies with Obesity and Cardiometabolic Pipelines Generic Drug Manufacturers Targeting Mature Oral Obesity Therapies CDMOs and API Manufacturers Supporting Oral Peptide and Small Molecule Production Obesity, Endocrinology and Metabolic Disease Clinics Retail, Specialty and Online Pharmacy Chains Telehealth and Digital Weight Management Platforms Health Insurance Companies, PBMs and Reimbursement Decision-Makers Investors, Venture Capital Firms and Strategic Healthcare Investors Suggestions for Related Report Suggestions for Related Report Anti-Obesity Drugs Market Weight loss therapeutics Market Glucagon-like Peptide 1 (GLP-1) Analogues Market Global Diabetes Drugs Market Insulin Resistance Market NASH/MASH Treatment Market Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drugs Market Cardiovascular Therapeutics Drugs Market Global Biosimilar Market
The largest research base of any peptide in the Durham Peptides catalog
Tirzepatide is the active ingredient in Zepbound, a GLP-1 receptor agonist
